EPZ6438 (also known as Tazemetostat or EPZ-6438) is a small molecule inhibitor that has been developed to target the enhancer of zeste homolog 2 (EZH2) protein. This product has shown potential as a therapeutic agent for various types of cancer, including lymphoma and solid tumors.
Chemical name: N-[(4,6-Dimethyl-2-pyridinyl)methyl]-1-(2,2,2-trifluoroethyl)-1H-pyrazole-5-carboxamide
Molecular formula: C34H44F3N5O2
Formula weight: 559.76 g/mol
CAS No: 1403254-99-8
Top ten keywords from Google:
Health benefits of this product: The primary health benefit of EPZ6438 is its potential ability to inhibit the EZH2 protein, which is an epigenetic regulator that is over-expressed in various types of cancer cells. By inhibiting EZH2, EPZ6438 may restore gene expression and prevent cancer progression.
Potential effects: Due to its ability to inhibit EZH2, EPZ6438 has shown promise as a therapeutic agent for various types of cancers, including lymphoma, breast cancer, prostate cancer, and many others. In preclinical studies, EPZ6438 has been shown to significantly reduce tumor growth and increase survival rates in animal models.
Product mechanism: EPZ6438 works by selectively inhibiting the activity of EZH2, which is a histone methyltransferase responsible for adding methyl groups to histones, thereby repressing the transcription of tumor suppressor genes. By inhibiting EZH2, EPZ6438 can prevent the methylation of histones, leading to the re-expression of silenced tumor suppressors.
Safety: Although EPZ6438 has shown promising results in preclinical studies, its safety profile in humans is still being studied. In clinical trials, some adverse effects have been reported, including fatigue, nausea, and vomiting, among others. However, these side effects were generally mild and well-tolerated.
Side effects: As with any medication, there is a risk of side effects when taking EPZ6438. Some potential side effects include headache, fatigue, dizziness, nausea, vomiting, and diarrhea. If you experience any of these symptoms while taking EPZ6438, you should consult your healthcare provider immediately.
Dosing information: The optimal dosing regimen for EPZ6438 has not yet been established. However, current clinical trials are investigating doses ranging from 200mg to 1800mg per day. Patients should follow their healthcare provider's instructions regarding dosing and administration.
Conclusion: EPZ6438 is a promising new EZH2 inhibitor that has shown significant potential as an anti-tumor agent in preclinical studies. Although its safety and efficacy in humans are still being evaluated, early results suggest that it may be a valuable addition to the arsenal of cancer therapies. As further research is conducted, EPZ6438 may prove to be a valuable tool in the fight against cancer